Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests which breathing aid works best for heart failure patients coming off ventilators

NCT ID NCT06671015

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times

Summary

This study compares two breathing support methods—high-flow nasal cannula (HFNC) and non-invasive ventilation (NIV)—in heart failure patients after their breathing tube is removed. The goal is to see which method better prevents the need for re-insertion of the breathing tube or respiratory failure within 72 hours. The trial will enroll 50 high-risk patients with systolic heart failure at Yale New Haven Hospital.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yale New Haven Hospital (CICU or MICU)

    RECRUITING

    New Haven, Connecticut, 06520, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

High-flow nasal cannula (HFNC) and non-invasive ventilation (NIV) devices

What this could lead to

If it works, this could show that high-flow nasal cannula is a better or equally effective way to prevent reintubation in heart failure patients, potentially improving recovery and reducing complications.

What could go wrong

This is a small pilot study with only 50 participants, so results may not apply to all patients. The open-label design means both doctors and patients know which treatment is given, which could bias outcomes.

Conditions

The condition(s) this trial relates to.

respiratory failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.